Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.
Int J Mol Sci
; 22(22)2021 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1524026
ABSTRACT
The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Regeneración
/
Trasplante de Células Madre Mesenquimatosas
/
Inmunomodulación
/
COVID-19
Tipo de estudio:
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
Idioma:
Inglés
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Ijms222212421
Similares
MEDLINE
...
LILACS
LIS